

CHEMBIO DIAGNOSTICS, INC.  
Form 8-K  
January 17, 2017

---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 17, 2017 (January 17, 2017)

CHEMBIO DIAGNOSTICS, INC.  
(Exact name of registrant as specified in its charter)

|   |   |   |
|---|---|---|
| Nevada<br>(State or other jurisdiction<br>of Incorporation) | 0-30379<br>(Commission File Number)   | 88-0425691<br>(IRS Employer<br>Identification Number) |
|   | 3661 Horseblock Road<br>Medford, NY 11763<br>(Address of principal executive offices) |   |
|   | 631-924-1135<br>(Registrant's Telephone Number)                                       |   |

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---



ITEM 7.01. REGULATION FD DISCLOSURE.

On January 17, 2017, the Company issued a press release entitled "Chembio's DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous Point-of-Care Detection of HIV and Syphilis". A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1 Press Release entitled "Chembio's DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous Point-of-Care Detection of HIV and Syphilis" dated January 17, 2017.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

January 17, 2017                      Chembio Diagnostics, Inc.

By: /s/ John J. Sperzel III  
John J. Sperzel III  
Chief Executive Officer

---

EXHIBIT INDEX

| Exhibit Number | Description   |
|----------------|---|
| 99.1           | Press Release entitled "Chembio's DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous |

Point-of-Care Detection of HIV and Syphilis" dated January 17, 2017.

---